Subscribe
Photo Nature Travel / Shutterstock.com
17 July 2025NewsEuropeMuireann Bolger

AstraZeneca suffers defeat over $7bn diabetes patent

Pharma giant can’t stop generics from unveiling copies of flagship product | Lord Justice Arnold upholds UK findings of lack of inventive step and insufficiency.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
AstraZeneca to appeal invalidated diabetes patent in generics dispute
29 April 2025   EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal.
Big Pharma
AstraZeneca fends off diabetes generic, for now
10 April 2025   Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Europe
AstraZeneca to appeal invalidated diabetes patent in generics dispute
29 April 2025   EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal.
Big Pharma
AstraZeneca fends off diabetes generic, for now
10 April 2025   Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

More on this story

Europe
AstraZeneca to appeal invalidated diabetes patent in generics dispute
29 April 2025   EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal.
Big Pharma
AstraZeneca fends off diabetes generic, for now
10 April 2025   Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

More features

US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator